These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10274713)

  • 1. Medicine's "gray market"': why alarm bells are ringing.
    Gest T; Lanier LK
    US News World Rep; 1985 Dec; 99(23):52. PubMed ID: 10274713
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA takes action against firms in scandal over generic products.
    Pollner F
    Med World News; 1989 Sep; 30(17):14-5. PubMed ID: 10294736
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives. FDA scandal: white hats, black hats, gray areas.
    Wiener JO
    Faulkner Grays Med Health; 1989 Dec; 43(48):suppl 6 p.. PubMed ID: 10296081
    [No Abstract]   [Full Text] [Related]  

  • 4. ASHP congressional testimony on the "gray market" in pharmaceuticals.
    Am J Hosp Pharm; 1986 Feb; 43(2):426-9. PubMed ID: 3953608
    [No Abstract]   [Full Text] [Related]  

  • 5. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
    Niedelman SM
    Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
    [No Abstract]   [Full Text] [Related]  

  • 6. Deterring the importation of counterfeit pharmaceutical products.
    Stearn DW
    Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug detailing in the hospital: background for policy development.
    Chan J; Einarson T
    Can J Hosp Pharm; 1991 Jun; 44(3):161-6. PubMed ID: 10112744
    [No Abstract]   [Full Text] [Related]  

  • 8. Hospital policies on pharmaceutical sales representatives' activities.
    Oddis JA
    Resid Staff Physician; 1987 Sep; 33(10):8. PubMed ID: 10284382
    [No Abstract]   [Full Text] [Related]  

  • 9. Reporting drug product defects--JCAHO.
    Hoffmann RP
    Hosp Pharm; 1989 Feb; 24(2):143-4. PubMed ID: 10318199
    [No Abstract]   [Full Text] [Related]  

  • 10. Shades of gray. Secondary drug distributors raise questions.
    Lee J
    Mod Healthc; 2011 Oct; 41(41):10, 12. PubMed ID: 22111494
    [No Abstract]   [Full Text] [Related]  

  • 11. Hospital pharmacists seek to control sales rep activities.
    Alt SJ
    Hosp Mater Manage; 1992 Apr; 17(4):2, 16. PubMed ID: 10170987
    [No Abstract]   [Full Text] [Related]  

  • 12. Bureaucratic overkill.
    Feldmann EG
    J Pharm Sci; 1979 May; 68(5):I. PubMed ID: 430486
    [No Abstract]   [Full Text] [Related]  

  • 13. Minimizing the influence of drug marketing.
    Hester FG
    Hospitals; 1990 Aug; 64(15):80. PubMed ID: 2373503
    [No Abstract]   [Full Text] [Related]  

  • 14. Generics still a favorite Rx for savings.
    Wagner M
    Mod Healthc; 1990 May; 20(21):26-8, 30, 32-3. PubMed ID: 10104890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fake biotech drugs raise concerns.
    Fox JL
    Nat Biotechnol; 2001 Jul; 19(7):603. PubMed ID: 11433258
    [No Abstract]   [Full Text] [Related]  

  • 16. Masterminds behind pharmaceutical fraud deserve prison time.
    White J
    Nat Med; 2010 Sep; 16(9):956. PubMed ID: 20823868
    [No Abstract]   [Full Text] [Related]  

  • 17. Legal implications of hospital resales of pharmaceuticals. American Hospital Association Office of General Counsel.
    Am J Hosp Pharm; 1986 Aug; 43(8):1951-7. PubMed ID: 3752135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug diversion by hospitals.
    Provost GP
    Am J Hosp Pharm; 1968 Apr; 25(4):159. PubMed ID: 5655783
    [No Abstract]   [Full Text] [Related]  

  • 19. Quality control of drugs.
    Whittet TD
    J Ir Med Assoc; 1968 Oct; ():Suppl 1:15-9. PubMed ID: 5701292
    [No Abstract]   [Full Text] [Related]  

  • 20. Adequate and sensible quality control.
    Schoulund B
    J Ir Med Assoc; 1968 Oct; ():Suppl 1:21. PubMed ID: 5701294
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.